TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Omalizumab Biosimilars Market Research Report 2022

Global Omalizumab Biosimilars Market Research Report 2022

  • Category:Life Sciences
  • Published on : 12 June 2022
  • Pages :97
  • Formats:
  • Report Code:SMR-7147251
OfferClick for best price

Best Price: $2320

Omalizumab Biosimilars Market Size, Share 2022


Market Analysis and Insights: Global Omalizumab Biosimilars Market

The global Omalizumab Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Omalizumab Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Omalizumab Biosimilars market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Omalizumab Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Omalizumab Biosimilars market.

Global Omalizumab Biosimilars Scope and Market Size

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

Segment by Application

  • Persistent Asthma
  • Nasal Polyps
  • Chronic Idiopathic Urticaria

By Region

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • China Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE

By Company

  • Roche
  • Novartis
  • Glenmark Pharmaceuticals
  • Selexis
  • Generium
  • CuraTeQ
  • Celltrion Healthcare
  • Alvotech
  • BiosanaPharma
  • Mabpharm
  • CSPC Pharmaceutical Group
  • Biomabs
  • HisunPharm
  • Grand Pharm

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Omalizumab Biosimilars product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Omalizumab Biosimilars, with price, sales, revenue, and global market share of Omalizumab Biosimilars from 2019 to 2022.

Chapter 3, the Omalizumab Biosimilars competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Omalizumab Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Omalizumab Biosimilars market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Omalizumab Biosimilars.

Chapter 13, 14, and 15, to describe Omalizumab Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Omalizumab Biosimilars Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Omalizumab Biosimilars Market Research Report 2022
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 97 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Omalizumab Biosimilars Market Overview
1.1 Product Overview and Scope of Omalizumab Biosimilars
1.2 Omalizumab Biosimilars Segment by Type
1.2.1 Global Omalizumab Biosimilars Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 150 mg/mL
1.2.3 75 mg/0.5 mL
1.3 Omalizumab Biosimilars Segment by Application
1.3.1 Global Omalizumab Biosimilars Sales Comparison by Application: (2022-2028)
1.3.2 Persistent Asthma
1.3.3 Nasal Polyps
1.3.4 Chronic Idiopathic Urticaria
1.4 Global Omalizumab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Omalizumab Biosimilars Revenue 2017-2028
1.4.2 Global Omalizumab Biosimilars Sales 2017-2028
1.4.3 Omalizumab Biosimilars Market Size by Region: 2017 Versus 2021 Versus 2028
2 Omalizumab Biosimilars Market Competition by Manufacturers
2.1 Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2017-2022)
2.2 Global Omalizumab Biosimilars Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Omalizumab Biosimilars Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Omalizumab Biosimilars Manufacturing Sites, Area Served, Product Type
2.5 Omalizumab Biosimilars Market Competitive Situation and Trends
2.5.1 Omalizumab Biosimilars Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Omalizumab Biosimilars Players Market Share by Revenue
2.5.3 Global Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Omalizumab Biosimilars Retrospective Market Scenario by Region
3.1 Global Omalizumab Biosimilars Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Omalizumab Biosimilars Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Omalizumab Biosimilars Market Facts & Figures by Country
3.3.1 North America Omalizumab Biosimilars Sales by Country
3.3.2 North America Omalizumab Biosimilars Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Omalizumab Biosimilars Market Facts & Figures by Country
3.4.1 Europe Omalizumab Biosimilars Sales by Country
3.4.2 Europe Omalizumab Biosimilars Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Omalizumab Biosimilars Market Facts & Figures by Region
3.5.1 Asia Pacific Omalizumab Biosimilars Sales by Region
3.5.2 Asia Pacific Omalizumab Biosimilars Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Omalizumab Biosimilars Market Facts & Figures by Country
3.6.1 Latin America Omalizumab Biosimilars Sales by Country
3.6.2 Latin America Omalizumab Biosimilars Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Omalizumab Biosimilars Market Facts & Figures by Country
3.7.1 Middle East and Africa Omalizumab Biosimilars Sales by Country
3.7.2 Middle East and Africa Omalizumab Biosimilars Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Omalizumab Biosimilars Historic Market Analysis by Type
4.1 Global Omalizumab Biosimilars Sales Market Share by Type (2017-2022)
4.2 Global Omalizumab Biosimilars Revenue Market Share by Type (2017-2022)
4.3 Global Omalizumab Biosimilars Price by Type (2017-2022)
5 Global Omalizumab Biosimilars Historic Market Analysis by Application
5.1 Global Omalizumab Biosimilars Sales Market Share by Application (2017-2022)
5.2 Global Omalizumab Biosimilars Revenue Market Share by Application (2017-2022)
5.3 Global Omalizumab Biosimilars Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Roche Omalizumab Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Novartis Omalizumab Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Glenmark Pharmaceuticals
6.3.1 Glenmark Pharmaceuticals Corporation Information
6.3.2 Glenmark Pharmaceuticals Description and Business Overview
6.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Portfolio
6.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.4 Selexis
6.4.1 Selexis Corporation Information
6.4.2 Selexis Description and Business Overview
6.4.3 Selexis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Selexis Omalizumab Biosimilars Product Portfolio
6.4.5 Selexis Recent Developments/Updates
6.5 Generium
6.5.1 Generium Corporation Information
6.5.2 Generium Description and Business Overview
6.5.3 Generium Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Generium Omalizumab Biosimilars Product Portfolio
6.5.5 Generium Recent Developments/Updates
6.6 CuraTeQ
6.6.1 CuraTeQ Corporation Information
6.6.2 CuraTeQ Description and Business Overview
6.6.3 CuraTeQ Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.6.4 CuraTeQ Omalizumab Biosimilars Product Portfolio
6.6.5 CuraTeQ Recent Developments/Updates
6.7 Celltrion Healthcare
6.6.1 Celltrion Healthcare Corporation Information
6.6.2 Celltrion Healthcare Description and Business Overview
6.6.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Celltrion Healthcare Omalizumab Biosimilars Product Portfolio
6.7.5 Celltrion Healthcare Recent Developments/Updates
6.8 Alvotech
6.8.1 Alvotech Corporation Information
6.8.2 Alvotech Description and Business Overview
6.8.3 Alvotech Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Alvotech Omalizumab Biosimilars Product Portfolio
6.8.5 Alvotech Recent Developments/Updates
6.9 BiosanaPharma
6.9.1 BiosanaPharma Corporation Information
6.9.2 BiosanaPharma Description and Business Overview
6.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.9.4 BiosanaPharma Omalizumab Biosimilars Product Portfolio
6.9.5 BiosanaPharma Recent Developments/Updates
6.10 Mabpharm
6.10.1 Mabpharm Corporation Information
6.10.2 Mabpharm Description and Business Overview
6.10.3 Mabpharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Mabpharm Omalizumab Biosimilars Product Portfolio
6.10.5 Mabpharm Recent Developments/Updates
6.11 CSPC Pharmaceutical Group
6.11.1 CSPC Pharmaceutical Group Corporation Information
6.11.2 CSPC Pharmaceutical Group Omalizumab Biosimilars Description and Business Overview
6.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Portfolio
6.11.5 CSPC Pharmaceutical Group Recent Developments/Updates
6.12 Biomabs
6.12.1 Biomabs Corporation Information
6.12.2 Biomabs Omalizumab Biosimilars Description and Business Overview
6.12.3 Biomabs Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Biomabs Omalizumab Biosimilars Product Portfolio
6.12.5 Biomabs Recent Developments/Updates
6.13 HisunPharm
6.13.1 HisunPharm Corporation Information
6.13.2 HisunPharm Omalizumab Biosimilars Description and Business Overview
6.13.3 HisunPharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.13.4 HisunPharm Omalizumab Biosimilars Product Portfolio
6.13.5 HisunPharm Recent Developments/Updates
6.14 Grand Pharm
6.14.1 Grand Pharm Corporation Information
6.14.2 Grand Pharm Omalizumab Biosimilars Description and Business Overview
6.14.3 Grand Pharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Grand Pharm Omalizumab Biosimilars Product Portfolio
6.14.5 Grand Pharm Recent Developments/Updates
7 Omalizumab Biosimilars Manufacturing Cost Analysis
7.1 Omalizumab Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Omalizumab Biosimilars
7.4 Omalizumab Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Omalizumab Biosimilars Distributors List
8.3 Omalizumab Biosimilars Customers
9 Omalizumab Biosimilars Market Dynamics
9.1 Omalizumab Biosimilars Industry Trends
9.2 Omalizumab Biosimilars Market Drivers
9.3 Omalizumab Biosimilars Market Challenges
9.4 Omalizumab Biosimilars Market Restraints
10 Global Market Forecast
10.1 Omalizumab Biosimilars Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Omalizumab Biosimilars by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Omalizumab Biosimilars by Type (2023-2028)
10.2 Omalizumab Biosimilars Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Omalizumab Biosimilars by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Omalizumab Biosimilars by Application (2023-2028)
10.3 Omalizumab Biosimilars Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Omalizumab Biosimilars by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Omalizumab Biosimilars by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Omalizumab Biosimilars Sales Growth Rate Comparison by Type (2022-2028) & (Units) & (US$ Million)
Table 2. Global Omalizumab Biosimilars Sales Growth Rate Comparison by Application (2022-2028) & (Units) & (US$ Million)
Table 3. Global Omalizumab Biosimilars Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Omalizumab Biosimilars Market Competitive Situation by Manufacturers in 2021
Table 5. Global Omalizumab Biosimilars Sales (Units) of Key Manufacturers (2017-2022)
Table 6. Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Omalizumab Biosimilars Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Omalizumab Biosimilars Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Omalizumab Biosimilars Average Price (K USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Omalizumab Biosimilars Manufacturing Sites and Area Served
Table 11. Manufacturers Omalizumab Biosimilars Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Omalizumab Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Omalizumab Biosimilars as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Omalizumab Biosimilars Sales by Region (2017-2022) & (Units)
Table 16. Global Omalizumab Biosimilars Sales Market Share by Region (2017-2022)
Table 17. Global Omalizumab Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Omalizumab Biosimilars Revenue Market Share by Region (2017-2022)
Table 19. North America Omalizumab Biosimilars Sales by Country (2017-2022) & (Units)
Table 20. North America Omalizumab Biosimilars Sales Market Share by Country (2017-2022)
Table 21. North America Omalizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Omalizumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 23. Europe Omalizumab Biosimilars Sales by Country (2017-2022) & (Units)
Table 24. Europe Omalizumab Biosimilars Sales Market Share by Country (2017-2022)
Table 25. Europe Omalizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Omalizumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Omalizumab Biosimilars Sales by Region (2017-2022) & (Units)
Table 28. Asia Pacific Omalizumab Biosimilars Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Omalizumab Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Omalizumab Biosimilars Revenue Market Share by Region (2017-2022)
Table 31. Latin America Omalizumab Biosimilars Sales by Country (2017-2022) & (Units)
Table 32. Latin America Omalizumab Biosimilars Sales Market Share by Country (2017-2022)
Table 33. Latin America Omalizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Omalizumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Omalizumab Biosimilars Sales by Country (2017-2022) & (Units)
Table 36. Middle East and Africa Omalizumab Biosimilars Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Omalizumab Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Omalizumab Biosimilars Revenue Market Share by Country (2017-2022)
Table 39. Global Omalizumab Biosimilars Sales by Type (2017-2022) & (Units)
Table 40. Global Omalizumab Biosimilars Sales Market Share by Type (2017-2022)
Table 41. Global Omalizumab Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Omalizumab Biosimilars Revenue Share by Type (2017-2022)
Table 43. Global Omalizumab Biosimilars Price by Type (2017-2022) & (K USD/Unit)
Table 44. Global Omalizumab Biosimilars Sales (Units) by Application (2017-2022)
Table 45. Global Omalizumab Biosimilars Sales Market Share by Application (2017-2022)
Table 46. Global Omalizumab Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Omalizumab Biosimilars Revenue Share by Application (2017-2022)
Table 48. Global Omalizumab Biosimilars Price by Application (2017-2022) & (K USD/Unit)
Table 49. Roche Corporation Information
Table 50. Roche Description and Business Overview
Table 51. Roche Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 52. Roche Omalizumab Biosimilars Product
Table 53. Roche Recent Developments/Updates
Table 54. Novartis Corporation Information
Table 55. Novartis Description and Business Overview
Table 56. Novartis Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 57. Novartis Omalizumab Biosimilars Product
Table 58. Novartis Recent Developments/Updates
Table 59. Glenmark Pharmaceuticals Corporation Information
Table 60. Glenmark Pharmaceuticals Description and Business Overview
Table 61. Glenmark Pharmaceuticals Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 62. Glenmark Pharmaceuticals Omalizumab Biosimilars Product
Table 63. Glenmark Pharmaceuticals Recent Developments/Updates
Table 64. Selexis Corporation Information
Table 65. Selexis Description and Business Overview
Table 66. Selexis Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 67. Selexis Omalizumab Biosimilars Product
Table 68. Selexis Recent Developments/Updates
Table 69. Generium Corporation Information
Table 70. Generium Description and Business Overview
Table 71. Generium Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 72. Generium Omalizumab Biosimilars Product
Table 73. Generium Recent Developments/Updates
Table 74. CuraTeQ Corporation Information
Table 75. CuraTeQ Description and Business Overview
Table 76. CuraTeQ Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 77. CuraTeQ Omalizumab Biosimilars Product
Table 78. CuraTeQ Recent Developments/Updates
Table 79. Celltrion Healthcare Corporation Information
Table 80. Celltrion Healthcare Description and Business Overview
Table 81. Celltrion Healthcare Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 82. Celltrion Healthcare Omalizumab Biosimilars Product
Table 83. Celltrion Healthcare Recent Developments/Updates
Table 84. Alvotech Corporation Information
Table 85. Alvotech Description and Business Overview
Table 86. Alvotech Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 87. Alvotech Omalizumab Biosimilars Product
Table 88. Alvotech Recent Developments/Updates
Table 89. BiosanaPharma Corporation Information
Table 90. BiosanaPharma Description and Business Overview
Table 91. BiosanaPharma Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 92. BiosanaPharma Omalizumab Biosimilars Product
Table 93. BiosanaPharma Recent Developments/Updates
Table 94. Mabpharm Corporation Information
Table 95. Mabpharm Description and Business Overview
Table 96. Mabpharm Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 97. Mabpharm Omalizumab Biosimilars Product
Table 98. Mabpharm Recent Developments/Updates
Table 99. CSPC Pharmaceutical Group Corporation Information
Table 100. CSPC Pharmaceutical Group Description and Business Overview
Table 101. CSPC Pharmaceutical Group Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 102. CSPC Pharmaceutical Group Omalizumab Biosimilars Product
Table 103. CSPC Pharmaceutical Group Recent Developments/Updates
Table 104. Biomabs Corporation Information
Table 105. Biomabs Description and Business Overview
Table 106. Biomabs Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 107. Biomabs Omalizumab Biosimilars Product
Table 108. Biomabs Recent Developments/Updates
Table 109. HisunPharm Corporation Information
Table 110. HisunPharm Description and Business Overview
Table 111. HisunPharm Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 112. HisunPharm Omalizumab Biosimilars Product
Table 113. HisunPharm Recent Developments/Updates
Table 114. Grand Pharm Corporation Information
Table 115. Grand Pharm Description and Business Overview
Table 116. Grand Pharm Omalizumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 117. Grand Pharm Omalizumab Biosimilars Product
Table 118. Grand Pharm Recent Developments/Updates
Table 119. Production Base and Market Concentration Rate of Raw Material
Table 120. Key Suppliers of Raw Materials
Table 121. Omalizumab Biosimilars Distributors List
Table 122. Omalizumab Biosimilars Customers List
Table 123. Omalizumab Biosimilars Market Trends
Table 124. Omalizumab Biosimilars Market Drivers
Table 125. Omalizumab Biosimilars Market Challenges
Table 126. Omalizumab Biosimilars Market Restraints
Table 127. Global Omalizumab Biosimilars Sales Forecast by Type (2023-2028) & (Units)
Table 128. Global Omalizumab Biosimilars Sales Market Share Forecast by Type (2023-2028)
Table 129. Global Omalizumab Biosimilars Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 130. Global Omalizumab Biosimilars Revenue Market Share Forecast by Type (2023-2028)
Table 131. Global Omalizumab Biosimilars Sales Forecast by Application (2023-2028) & (Units)
Table 132. Global Omalizumab Biosimilars Sales Market Share Forecast by Application (2023-2028)
Table 133. Global Omalizumab Biosimilars Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 134. Global Omalizumab Biosimilars Revenue Market Share Forecast by Application (2023-2028)
Table 135. Global Omalizumab Biosimilars Sales Forecast by Region (2023-2028) & (Units)
Table 136. Global Omalizumab Biosimilars Sales Market Share Forecast by Region (2023-2028)
Table 137. Global Omalizumab Biosimilars Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 138. Global Omalizumab Biosimilars Revenue Market Share Forecast by Region (2023-2028)
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Omalizumab Biosimilars
Figure 2. Global Omalizumab Biosimilars Market Share by Type in 2021 & 2028
Figure 3. 150 mg/mL Product Picture
Figure 4. 75 mg/0.5 mL Product Picture
Figure 5. Global Omalizumab Biosimilars Market Share by Application in 2021 & 2028
Figure 6. Persistent Asthma
Figure 7. Nasal Polyps
Figure 8. Chronic Idiopathic Urticaria
Figure 9. Global Omalizumab Biosimilars Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 10. Global Omalizumab Biosimilars Market Size (2017-2028) & (US$ Million)
Figure 11. Global Omalizumab Biosimilars Sales (2017-2028) & (Units)
Figure 12. Omalizumab Biosimilars Sales Share by Manufacturers in 2021
Figure 13. Global Omalizumab Biosimilars Revenue Share by Manufacturers in 2021
Figure 14. The Global 5 and 10 Largest Omalizumab Biosimilars Players: Market Share by Revenue in 2021
Figure 15. Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 16. Global Omalizumab Biosimilars Sales Market Share by Region (2017-2022)
Figure 17. Global Omalizumab Biosimilars Sales Market Share by Region in 2021
Figure 18. Global Omalizumab Biosimilars Revenue Market Share by Region (2017-2022)
Figure 19. Global Omalizumab Biosimilars Revenue Market Share by Region in 2021
Figure 20. United States Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Canada Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Germany Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. France Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. U.K. Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Italy Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Russia Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. China Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Japan Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. South Korea Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. India Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Australia Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. China Taiwan Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Indonesia Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Thailand Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Malaysia Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Mexico Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Brazil Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Argentina Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Turkey Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Saudi Arabia Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. UAE Omalizumab Biosimilars Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Sales Market Share of Omalizumab Biosimilars by Type (2017-2022)
Figure 43. Manufacturing Cost Structure of Omalizumab Biosimilars
Figure 44. Manufacturing Process Analysis of Omalizumab Biosimilars
Figure 45. Omalizumab Biosimilars Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount